Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
← catalyst calendarNCT03953300 · readout in 61 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
75actual
Sites
35
Countries
Canada, Denmark, Sweden +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-08 | actual | When the study began enrolling |
| Primary completion | 2026-10-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-19 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Biological: Benralizumab
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFThe change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies
measured From baseline to Week 48 (Visit 10)
The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imaging
measured From baseline to Week 48 (Visit 10)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed